A randomized, controlled phase 1b trial evaluated the safety, pharmacokinetics and impact on viral kinetics of budigalimab, a PD-1 inhibitor, during analytical treatment interruption for HIV and found that it was well tolerated and resulted in delayed rebound in a subset of participants in an exploratory efficacy analysis.
- Moti N. Ramgopal
- Jacob P. Lalezari
- Jean-Pierre Routy
